DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Marinol (Dronabinol) - Summary

 
 



MARINOL SUMMARY

MARINOL®
(dronabinol)
Capsules

Dronabinol is a cannabinoid designated chemically as (6 aR-trans) -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo[ b,d ]pyran-1-ol.

MARINOL® (Dronabinol) Capsules is indicated for the treatment of:

  1. anorexia associated with weight loss in patients with AIDS; and
  2. nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.


See all Marinol indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Marinol (Dronabinol)

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. [2011.07.01]
Cannabis dependence is a substantial public health problem. Behavioral treatments have shown promise, but there are no effective medications for cannabis dependence... Future trials might test higher doses, combinations of dronabinol with other medications with complementary mechanisms, or with more potent behavioral interventions.

Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. [2010.01.01]
The purpose of this study was to determine whether Delta(9)-tetrahydrocannabivarin (THCV), a plant cannabinoid, is a sensitive measure to detect recent marijuana use in cannabis dependent patients. It has been purported that smoking an illicit plant cannabis product will result in a positive THCV urinalysis, whereas the oral ingestion of therapeutic THC such as dronabinol will result in a negative THCV urinalysis, allowing for discrimination between pharmaceutical THC products and illicit marijuana products...

Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2008.03]
We assessed the efficacy of dronabinol (Marinol capsules; Solvay Pharmaceuticals, Brussels, Belgium), a synthetic Delta(9)-THC (tetrahydrocannabinol), in 30 patients taking opioids for chronic pain to determine its potential analgesic effects as an adjuvant treatment...

Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay. [2008.01]
BACKGROUND: Serum blood toxicology screens are believed to be important to monitor compliance and to identify levels of illicit substances in patients taking opioids for their chronic pain... CONCLUSIONS: These toxicology reports point to higher than anticipatedfalse-negative results with radioimmunoassay blood serum screening. Results could be explained by the lower sensitivity of this screening technique and also in how oral cannabinoids are metabolized. Further investigations are needed on the accuracy of the detection of THC among patients known to have used dronabinol.

Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2007.12.12]
We assessed the efficacy of dronabinol (Marinol capsules; Solvay Pharmaceuticals, Brussels, Belgium), a synthetic Delta(9)-THC (tetrahydrocannabinol), in 30 patients taking opioids for chronic pain to determine its potential analgesic effects as an adjuvant treatment...

more studies >>

Clinical Trials Related to Marinol (Dronabinol)

Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain [Active, not recruiting]
The purpose of this research study is to determine if Marinol alleviates pain in patients with chronic pain who are currently taking opioids.

The study begins with a 2-hour initial visit followed by three 8-hour appointments at Brigham and Women’s Hospital. At each 8-hour visit, patients receive a dose of medication and complete surveys relating to pain.

During the first visit a brief examination and a few surveys about pain, quality of life, and medical history are given. The study doctor then determines if the participant continues to qualify for the study.

If qualified for the study, patients receive a daily diary to record pain levels and pain medications; this will take about 5 minutes each day. After completion of the diary, patients begin the 8-hour visits.

Patients visit the Pain Trials Center three times to receive study medication. After taking the study medication, participants remain in the clinic for 8 hours to complete hourly surveys about pain and pain relief.

Subsequent to these visits, patients may enter a 1-month extension where Marinol is taken at home, and pain levels are recorded in a diary. Participants can change the dose of study drug to better control pain and side effects, after speaking with study staff. The study then concludes with a final 30-minute visit to summarize the participant’s experience in the clinical trial.

Dronabinol Treatment for Marijuana Addiction [Recruiting]
The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.

Effects of Dronabinol (Oral THC) on Cannabis Use [Recruiting]
The number of people seeking treatment for marijuana-related problems is on the rise, yet there is no currently accepted medication proven to help them quit. This research is designed to determine whether the FDA approved medication dronabinol (Marinol®) has effects that might help make it easier for people to stop daily marijuana use, and to carefully study the occurence of safety risks and side-effects at different doses of the drug.

Dronabinol Naltrexone Treatment for Opioid Dependence [Recruiting]
The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We hypothesize that administering dronabinol during detoxification and during the first few weeks of naltrexone treatment will lead to improved naltrexone tolerability, resulting in better naltrexone compliance and treatment retention, and ultimately a reduction in opioid use and relapse rates.

Marinol in Trichotillomania or Obsessive Compulsive Disorder [Recruiting]
The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in individuals with obsessive-compulsive disorder (OCD) or the obsessive-compulsive spectrum disorders, trichotillomania (TTM) or pathological skin picking (PSP). Fifteen patients with OCD, TTM, or PSP will receive 12 weeks of open-label treatment with dronabinol. The hypothesis to be tested is that dronabinol will be effective and well tolerated in patients with these disorders. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

more trials >>

Reports of Suspected Marinol (Dronabinol) Side Effects

Abdominal Pain (8)Dyskinesia (7)Pneumonia Fungal (6)Febrile Neutropenia (6)Confusional State (5)Clostridium Difficile Colitis (5)Fungal Rhinitis (5)OFF Label USE (5)Hallucination (5)Nausea (5)more >>


Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014